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Research Hospital Holy see; 102Department of Epidemiology, Regional Health Service Lazio Region, Rome, Italy; 103National Center for
Disease Control and Public Health of Georgia, Tbilisi, Georgia; 104Turkish Thoracic Society Asthma-Allergy Working Group, Kocaeli,
Turkey; 105Allergy and Immunology Division, Clinica Ricardo Palma, Lima, Peru; 106Sociedad Latinoamericana de Allergia, Asma e
Immunologia, Mexico City, Mexico; 107Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology,
Tbilisi, Georgia; 108Faculty of the Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA;
109Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile; 110Skin and Allergy Hospital, Helsinki University
Hospital, Helsinki, Finland; 111Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark; 112Institute of
Epidemiology I, German Research Centre for Environmental Health, Helmholtz Zentrum München, Neuherberg, Germany; 113Vienna
Challenge Chamber, Vienna, Austria; 114Department of Paediatrics and Child Health, University College Cork, Cork, Ireland; 115University of
Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK; 116Université Paris-Sud, Le Kremlin Bicêtre, France;
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Germany; 140Clı́nica de Alergia, Asma y Pediatrı́a, Hospital Médica Sur, México City, México; 141University of Medicine and Pharmacy,
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Pneumologie, University of Nantes, UMR INSERM, UMR1087/CNR 6291, l’Institut du Thorax, Nantes, France; 148Department of Pulmonary
Medicine, Rashid Hospital, Dubai, UAE; 149Department of Respiratory Medicine, University Hospital, Bratislava, Slovakia; 150Department of
Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland; 151Kronikgune, Basque Region, Spain; 152Division of Clinical Immunology
and Allergy, Laboratory of Behavioral Immunology Research, The University of Mississippi Medical Center, Jackson, MS, USA;
153Respiratory Disease Research, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 154Allergie-Centrum-Charité at the
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Universitätsklinikum der RWTH Aachen, Aachen, Deutschland; 159Croatian Pulmonary Society, Zagreb, Croatia; 160National Institute of
Pneumology M. Nasta, Bucharest, Romania; 161Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 162National Center for
Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syria; 163Département de Pharmacologie, CHU
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Switzerland; 212Allergy and Respiratory Research Group, Medical School, Centre for Population Health Sciences, The University of
Edinburgh, Edinburgh, UK; 213Department of Pediatrics & Child Health, Department of Immunology, Faculty of Medicine, University of
Manitoba, Winnipeg, MB, Canada; 214Sociedad Paraguaya de Alergia Asma e Inmunologıa, Paraguay, Paraguay; 215Julius Center of Health
Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands; 216Division of Allergy,
Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil; 217Kyrgyzstan National
Centre of Cardiology and Internal medicine, Euro-Asian respiratory Society, Bishkek, Kyrgyzstan; 218Pulmonary Division, Heart Institute
(InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; 219European Union
GeriatricMedicine Society, Vienna, Austria; 220Department of Epidemiology, CAPHRI School of Public Health and Primary Care, Maastricht
University, Maastricht, The Netherlands; 221Centre of Pneumology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal;
222Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy; 223Division of Immunopathology, Department of
Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna,
Austria; 224Pneumology and Allergy Department, Hospital Clı́nic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona,
Spain; 225Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and University Hospital, Stockholm,
Sweden; 226Department of Chest Medicine, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain, Yvoir,
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Abstract
Several unmet needs have been identified in allergic rhinitis: identification of the
time of onset of the pollen season, optimal control of rhinitis and comorbidities,
patient stratification, multidisciplinary team for integrated care pathways, innova-
tion in clinical trials and, above all, patient empowerment. MASK-rhinitis (MAC-
VIA-ARIA Sentinel NetworK for allergic rhinitis) is a simple system centred
around the patient which was devised to fill many of these gaps using Informa-
tion and Communications Technology (ICT) tools and a clinical decision support
system (CDSS) based on the most widely used guideline in allergic rhinitis and its
asthma comorbidity (ARIA 2015 revision). It is one of the implementation sys-
tems of Action Plan B3 of the European Innovation Partnership on Active and
Healthy Ageing (EIP on AHA). Three tools are used for the electronic monitor-
ing of allergic diseases: a cell phone-based daily visual analogue scale (VAS)
assessment of disease control, CARAT (Control of Allergic Rhinitis and Asthma
Test) and e-Allergy screening (premedical system of early diagnosis of allergy and
asthma based on online tools). These tools are combined with a clinical decision
support system (CDSS) and are available in many languages. An e-CRF and an
e-learning tool complete MASK. MASK is flexible and other tools can be added.
It appears to be an advanced, global and integrated ICT answer for many unmet
needs in allergic diseases which will improve policies and standards.
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Allergic rhinitis (AR) is among the most common diseases
globally (1) and ranks first in Europe (over 25% of the Euro-
pean population). It exists in all age groups, and it often
starts early in life (2) and persists across the life cycle (3, 4).
The burden and costs are substantial (5). It often impairs
social life, work and school performance (6–8) and has a
major impact on healthy ageing (9).
Several unmet needs have been identified. MASK-rhinitis
is a simple system centred around the patient. It has been
devised to fill many of the gaps using Information and Com-
munications Technology (ICT) tools and a clinical decision
support system (CDSS) based on the most widely used guide-
line in AR (ARIA) (10). It is a product of the European
Innovation Partnership on Active and Healthy Ageing (11)
and is currently being launched in 15 countries. Patient
empowerment is essential to the project. MASK-rhinitis rep-
resents a novel tool to diagnose, stratify and manage patients
with AR and to assess treatment efficacy. It has the potential
to have major impact on health policies and planning. In the
future, the combination with biomarkers will further improve
the impact of MASK-rhinitis.
MACVIA-LR (Fighting chronic diseases for active and
healthy ageing, http://macvia.cr-languedocroussillon.fr) is a
reference site of the European Innovation Partnership on
Active and Healthy Ageing (12). It initiated the project AIR-
WAYS ICPs, an integrated care pathway (ICP) for airway
diseases (13).
Unmet needs in allergic rhinitis
Early diagnosis and management of patients with respiratory
allergic diseases
Although AR is common in all age groups, it is very often
overlooked and under-diagnosed, especially in preschool chil-
dren and the elderly. The Polish Presidency of the EU Coun-
cil (2011) targeted chronic respiratory diseases in children to
promote their early recognition, prevention and management
and, ultimately, to promote AHA (9).
Clinical diagnosis is difficult, and symptoms may relate to
allergic and nonallergic rhinitis as well as rhinosinusitis (14).
There is a need for a simple diagnostic tool.
Patient stratification
The treatment of AR is now well established. Although the
majority of patients present with controlled symptoms during
pharmacologic treatment, 10–20% are still uncontrolled and
should be characterized as suffering from severe chronic
upper airway disease (SCUAD) (15). Patients with SCUAD
have impaired quality of life, sleep, school and/or work per-
formance (16, 17).
Many AR patients are over 65 years of age. The presenta-
tion of the disease, as well as the efficacy and safety of treat-
ments, may differ in older adults. However, data are not yet
available from RCTs.
Time of onset of the allergy season
For patients allergic to pollen, knowledge of the onset of the
pollen season is of vital importance in order to start treatment
as early as possible for the control of symptoms. When travel-
ling, patients are often concerned about potential symptoms
and/or bothered by symptoms outside their usual symptom
‘window’. It is therefore of importance to forecast the onset of
the pollen season and to characterize seasons in different
places.
Pollen counts are currently proposed to assess the exposure
of pollen-allergic patients. However, counts often correlate
imperfectly with symptoms (18–22) as (i) they do not repre-
sent allergen exposure alone (19, 23, 24), (ii) the number of
pollen grains needed to elicit symptoms is not well defined
and differs depending on the pollen species, (iii) there is a
nonlinear relationship between pollen and allergic symptoms
(25, 26) and (iv) interactions between pollens and atmo-
spheric conditions or air pollution may exist (27, 28). Fur-
thermore, for large geographical areas, pollen samplers are
sparsely located. Patients may live at a distance from the
sampler, and the levels of allergens in their environment may
differ quite extensively from the levels detected by the sam-
pler. Individualized pollen counts would be preferable (29)
but are not feasible on a large scale. Finally, pollen counts
are only available several days after onset of the season.
The assessment of allergen content in the air is feasible
using antibody-based methods (18, 19, 30) or the biomolecu-
lar identification of pollen genomes (31). However, sophisti-
cated methods are required which may not account for all of
the pollen species in the ambient air, and individual measure-
ments are not feasible.
Meteorological data may, in the future, be of interest to
predict the onset of the season, but more information is
needed (32–35). Combining several data sources using
advanced data engineering may offer advances, but this
method is still complex and not available for all pollen spe-
cies in many different areas (36, 37).
Internet-based surveillance systems using search engine
queries (38) and social media (39) are recent techniques with
the potential to extend or even substitute the more costly dis-
Abbreviations
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ease surveillance systems (40). A few studies analysing online
searches of pollens, rhinitis symptoms and allergies have
shown associations with pollen counts (41). The analysis of
online searches, in particular using Google trends, has shown
potential in predicting changes in flu infections (42) and in
other areas of medicine (38). Nevertheless, this type of big data
analysis is just beginning (38) and more research is needed to
prove its value in predicting the onset of allergic rhinitis symp-
toms due to the pollen season (43). Moreover, the onset of the
pollen season cannot be predicted using these models.
In the meantime, other novel approaches such as a personal-
ized pollen-related forecast (44, 45) and an ICT sentinel network
based on patients’ symptoms should be developed. However,
these approaches need to be simple and user friendly.
Continuous management of symptoms during allergen
exposure
Allergen exposure varies daily, and patients with respiratory
allergic symptoms need regular monitoring of symptoms in
order to optimize treatment. A clinical decision support sys-
tem (CDSS) may be beneficial to optimize treatment and
assess disease control after commencement of the allergy sea-
son. Moreover, such a system has the potential to improve
patients’ compliance to treatment. Guided management of
allergic diseases including asthma was found to be effective
(46, 47) with clear evidence provided by the Finnish Asthma
Programme (48) and the Allergy Programme (49, 50).
Comorbidity assessment
Conjunctivitis, chronic rhinosinusitis and asthma are frequent
AR comorbidities that need to be identified and treated to
achieve good AR control (51). ICPs that include asthma screen-
ing and assessment, as recommended by ARIA (Allergic Rhini-
tis and its Impact on Asthma) (6, 7), may result in improved
outcomes and should be tested. In addition, optimal AR control
may facilitate the control of concomitant asthma.
Needs for a multidisciplinary team for an ICP
Integrated care pathways (ICPs) are structured multidisci-
plinary care plans which detail essential steps in the care of
patients with a specific clinical problem (52). They promote
the translation of guideline recommendations into local pro-
tocols and their subsequent application to clinical practice.
An ICP forms all or part of the clinical record, documents
the care given and facilitates the evaluation of outcomes for
continuous quality improvement (53). ICPs can help
empower patients and their care providers (health and
social). They differ from clinical practice guidelines as they
focus on the quality and co-ordination of care. ICPs need to
have a mechanism for recording variations/deviations from
planned care. Variation between recommendations and prac-
tice identified within an ICP should be noted as a variance
(54, 55). In AR, there is a need for ICPs to combine the
views of patients, pharmacists, primary care physicians, spe-
cialists, and other healthcare professionals.
Biomarkers in respiratory allergic diseases
Biomarkers are of great importance in respiratory allergic
diseases and asthma, and a large body of research is focusing on
their identification and validation. Biomarker identification can
be based on systems medicine approaches combining transcrip-
tomics, proteomics, epigenetics and metabolomics in large
patient cohorts. One recently completed EU project, MultiMod,
resulted in a generally applicable strategy to integrate such data
for diagnostic purposes using systems medicine principles (56).
Two EU-funded projects are currently ongoing: U-BIOPRED
(IMI) in severe asthma (57) and MeDALL (FP7) in allergy (58,
59). MeDALL has already made critical observations concern-
ing IgE biomarkers for the diagnosis and prognosis of allergic
diseases (2, 60). It is hoped that these projects will help identify
biomarkers to enhance personalized medicine (61, 62) and to
improve patient stratification and clinical trials. Another
ongoing EU project, CASyM, has generated a road map for the
implementation of systems medicine in clinical research and
practice (https://www.casym.eu/).
Innovation in clinical trials
In randomized controlled trials (RCTs), it is essential to have
clarity with regard to the definitions of disease severity and
control as well as comorbidities and risk factors (e.g. smok-
ing). RCT outcomes should be validated and standardized,
so that meaningful comparisons between RCTs can be made
(63). Several gaps exist in RCTs in respiratory allergy.
Among them the importance of the placebo effect and the
evaluation of efficacy using a single assessment tool combin-
ing symptoms, medications and quality of life (64). Novel
tools for the evaluation of RCTs on AR and its common
comorbidities are needed, if possible using ICT.
Climate change effects on allergic diseases
Allergy prevalence continues to grow due to novel interac-
tions between known allergens and other environmental fac-
tors. An increase in the prevalence and severity of allergy
and asthma is anticipated due to climate changes (65). Wors-
ening ambient air pollution and altered local and regional
allergen production (66) and reduction in biodiversity may
play a significant role (67). This anticipated higher allergic
disease burden will affect clinical practice as well as policies
and public health planning.
Patient empowerment
To satisfy patient expectations, asthma and AR should be
appropriately diagnosed and controlled. Patients need to be
motivated to become educated and to actively increase their
own health literacy to be able to take over the responsibility
of their own specific condition. Patient organizations have
been involved in the design, dissemination and implementa-
tion of ARIA. ICT can empower patients and thus enable
them to define specific goals and to monitor disease status
and control. It can also support the patient’s decisions.
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Tools
ARIA
ARIA was initiated during a WHO workshop in 1999 (pub-
lished in 2001) (6, 7). The ultimate aim of ARIA is to achieve
control of AR globally. ARIA has reclassified AR as mild/
moderate–severe and intermittent/persistent. This classifica-
tion closely reflects patients’ needs and underlines the close
relationship between rhinitis and asthma. A module devoted
to the pharmacist exists (68). In its 2010 Revision, ARIA
developed clinical practice guidelines for the management of
AR and asthma comorbidities based on GRADE (Grading
of Recommendation, Assessment, Development and Evalua-
tion) (69). ARIA is disseminated and implemented in over 60
countries of the world (10). ARIA has been endorsed by sev-
eral ministries of health.
Variance has been tested and it was found that the ARIA
classification of mild vs moderate–severe and intermittent vs
persistent rhinitis is valid. A modified ARIA severity classifi-
cation has also recently been validated as mild, moderate
and severe, both in adults (70) and children (71), although
its impact on treatment stratification remains an unmet
need.
The 2015 ARIA revision leading to ICPs was finalized and
presented at the AIRWAYS ICPs meeting in Lisbon 1–2 July
2015 (Figure 1).
Measures of allergic rhinitis control
Concepts of disease severity, activity, control and responsive-
ness to treatment are linked but constitute different domains
(72). Control and severity are not well delineated in AR (72).
Severity is the loss of function in the target organ(s) induced
by disease (73). It is important to highlight that severity may
vary over time and needs to be regularly re-evaluated (74).
Control is the degree to which therapy goals are currently
met (74) such as glycemic control in diabetes (75), and can
be assessed in patients before or during treatment to guide
therapy. However, for AR, the patients’ view of severity
relates to the negative impact that rhinitis has upon life; con-
trol is a measure by which their symptoms are alleviated.
Measures of AR control include (i) symptom scores,
(ii) patient self-administered visual analogue scales (VAS)
(16, 76–81), (iii) objective measures of nasal obstruction
(such as peak nasal inspiratory flow, acoustic rhinometry and
rhinomanometry) (82), (iv) a recent modification of the
ARIA severity classification (83), (v) patients’ reported out-
comes such as quality of life (QOL) (7, 63) scores with sev-
eral items (80, 84) or composite symptom-medication scores
(85). However, it is important to make the score for clinical
use simple and responsive to change.
VAS is a psychometric response scale for subjective charac-
teristics or attitudes used in a large variety of diseases. The
continuous (or ‘analogue’) aspect of VAS differentiates it from
discrete scales such as the Likert scale. The sensitivity and
reproducibility of VAS results are very similar, although the
VAS may outperform the other scales in some cases (86, 87).
In AR, VAS for all nasal symptoms appears to be suffi-
cient to appreciate disease control (88) and is particularly
relevant to primary (89) or pharmacy care (68). VAS can be
used in all age groups including preschool children (guardian
evaluation) (90) and the elderly (91). Furthermore, it can be
used in a wide variety of languages (81, 91–97). VAS levels
vary with the ARIA classification in many languages (76, 79,
Evidence to Decision Frameworks with ranking of an interven!on
allowing country (region) adapta!on
HCP views
Care pathway based on evidence to 
decision frameworks specific to
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- Age and sex
- Pa!ent stra!fica!on
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Step 2
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Figure 1 ARIA 2015.
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81, 98). A VAS level of 50 mm is suggestive of moderate–sev-
ere AR (99–101) although in some studies the cut-off was of
over 60 mm (94). VAS was used to define SCUAD (16), and
patients with a low VAS level after treatment had a consider-
ably improved Rhinoconjunctivitis Quality of Life Question-
naire (RQLQ) or work productivity (WPAI-AS). However,
those with a level of over 50 mm had no improvement. VAS
has been validated in cell phones (Sarah Acaster, personal
communication).
VAS was found to be responsive to change in real-life clus-
ter-randomized trials (102, 103). The minimal clinically rele-
vant difference was set for a VAS level of 23 mm during
treatment, whatever the baseline VAS level (104). A level of
over 23 mm appears to be a relevant cut-off. VAS changes
appear to encompass both symptoms and disease-specific
QOL (88, 104).
VAS was highly responsive to change in double-blind, pla-
cebo-controlled RCTs (92, 93, 102, 105–108). These multicen-
tre studies in Europe and Canada showed that patients easily
cope with VAS in different languages.
These studies combine to indicate that VAS may be a
simple and useful tool for the assessment of AR control and
to follow the efficacy of treatment.
Electronic monitoring of allergic diseases
e-Allergy screening: Premedical system of early diagnosis of
allergy and asthma based on online tools
The late diagnosis of allergic diseases and asthma is a serious
problem. Patients with first symptoms of respiratory allergies
are often misclassified in primary care. As a result, patients
are either untreated or treated symptomatically, generally for
a long period of time. This behaviour is detrimental to the
patient, the healthcare system and the society, as it impacts
on indirect costs (5).
One solution to this problem was presented in 2011 at a
conference of experts during the Polish Presidency of the EU
Council (109). It is an e-Allergy – premedical system capable
of providing an early diagnosis of allergy and asthma on the
basis of online tools. The concept is based on a screening
questionnaire with built-in algorithms. It assesses individual
risk of allergic diseases and includes 24 questions. The pro-
cess takes about 5 minutes. The questions are selected
depending on previous responses. The result is displayed in
the form of risk calculation for the selected allergic diseases
(asthma, allergic rhinitis, atopic dermatitis and allergy to
Hymenoptera venom).
To develop the algorithm, data from the Epidemiology of
Allergy in Poland (ECAP) (www.ecap.pl) were used (110).
Over 20 000 people responded to the study questionnaire, and
almost 5000 were subjected to additional allergological tests.
Various advanced methods of statistical analysis, including an
artificial neural network, have been used to develop the algo-
rithm. The system is calibrated to maximize the effectiveness
of a group of people suffering from allergic diseases.
E-allergy screening can be used both by the public with
suspected allergies and physicians. The initial diagnosis can
lead to an evaluation. It is performed by a primary health-
care professional and, if needed, confirmed by a specialist.
The role of e-allergy is to support, not replace, the physicians
and also to speed up the process of unrecognized allergic dis-
eases by proper management.
Daily tool based on VAS using cell phones
MASK aerobiology, approved by AIRWAYS-ICPs, is a very
simple IOS/Android App. It is already available and is being
expanded to other systems with interoperability. Patients
selected by physicians trained in allergy represent the
sentinels for the onset of the season. The VAS represents a
reliable and valid measure of rhinitis control (10, 72)
(Figure 2). It can be used across the life cycle (90, 91, 111).
CARAT
Asthma frequently occurs in association with allergic rhinitis,
and a combined management approach has been suggested.
The Control of Allergic Rhinitis and Asthma Test (CARAT)
is the first questionnaire to assess the control of both dis-
eases concurrently (112–115). An overall score of more than
24 indicates good control of asthma and rhinitis, while a
change of four points between two occasions indicates a clin-
ically relevant change (115). In addition, answers to individ-
ual questions may be used to identify the specific problems
of a patient (e.g. night symptoms or overuse of reliever medi-
cation). However, to have an impact on healthcare, it needs
to be disseminated and adopted. At present, the adaptation
of CARAT for use in different languages and cultures is
being led by volunteer researchers and clinicians in 15 coun-
tries. Website and smartphone applications have been devel-
oped, and a free open model of distribution has been
adopted to contribute to the dissemination of CARAT.
CARAT can be used in a range of settings and circum-
stances in primary and secondary care for clinical, research
and audit purposes, and also in ambulatory pharmacies
(116). It can be used both in adults and children (117, 118)
and strengthens the partnership between patients and doctors
in the management of asthma and rhinitis. CARAT can be
administered every 2–4 weeks both in paper and electronic
forms (119) and represents an additional tool for daily
assessment.
• ? Indicates a response is 
required
• Users touch the line to 
indicate response and a 
‘marker’ appears in that 
location
• The marker can be moved 
with a finger to mark the line 
where intended. 
• Once the mark is placed the 
user then touches ‘next’ to 
move on to the next VAS 
• Each VAS is completed 
once daily
Figure 2 MASK aerobiology.
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RhinAsthma Patient Perspective
‘RhinAsthma Patient Perspective (RAPP)’ is the first valid
questionnaire to assess the individual health-related QoL of
patients with asthma and rhinitis in clinical practice. It is a
simple eight-question tool with good measurement properties
and sensitivity to health changes. RAPP is easy to complete
and score, and the results enable immediate interpretation
both for the physician and for the patient. The score, calcu-
lated by summing the responses of each item, ranges from 8
(no impact on QoL) to 40 (the worst possible QoL). A cut-
off point of 15 has demonstrated the best sensitivity and
specificity in discriminating the achievement of an optimal
health-related QoL. A change of two points in the RAPP
score was found to be the minimal clinical difference that
patients perceived as important, either ‘beneficial or harmful.’
A new tool for the smartphone has been developed (120).
Clinical decision support system
Identifying the most suitable patients for whom an interven-
tion is appropriate is critical for the delivery of a cost-effective
health system. In many diseases, the management of patients
uses ICT tools including integrated care pathways, e-health
and CDSS. This has made a significant improvement and has
sometimes led to a change of management in health systems.
A CDSS (121, 122) immediately proposes advice for (stan-
dardized) pharmacologic treatment defined by the physician
during a consultation before the pollen season. Care pathways
based on AIRWAYS ICPs (13) will guide the healthcare pro-
fessional. Patients with SCUAD are defined as those resistant
to treatment despite optimal treatment (VAS level > 50%).
Moreover, individual complaints of rhinitis, conjunctivitis or
asthma are monitored by the system (123). Computer-anal-
ysed VAS responses may be measured using discrete values
due to the discrete nature of computer displays, and VAS can
be used in internet-based questionnaires (124).
Bias reduction, patient empowerment and identification of
new markers through a Living Lab approach
Systematically collecting and mining/analysing data from
patients’ mobile phones where they can enter quantitative
and qualitative information is indeed a promising use of
innovative health technologies (125). This should allow, on
an almost continuous mode, a long-term close monitoring of
and connection to the patient. To our knowledge, this has
not been addressed before by any other technology. How-
ever, a major requirement for the implementation of such
clinical protocols is the validity of data (125, 126). In validat-
ing such protocols, bias by the degree of usage of devices by
the patients and bias in information input due to the context
or human factors need to be identified and eradicated; such
factors are very difficult to control. The overall bias will nor-
mally be balanced by the long-term use of the application by
the patient, as patients’ data are always compared to their
previous declarations. However, it is possible and desirable
to improve the results and reduce the time necessary to
obtain them. Contrary to drugs, where the administration of
medications to patients may be appropriately controlled dur-
ing clinical trials, the usage of mobile phones, especially at
home, is known to depend heavily on (i) the usability of such
devices and supported applications, (ii) their context of use
(including ongoing activities, social environment, presence of
third parties), and (iii) the constraints they impose on
patients, with a strong probability of weak compliance, haz-
ardous on/off usage or even rejection and abandon by the
patients (127, 128). Similarly, the adoption of these new prac-
tices, including participation and interactions from family
members or professionals, is an issue (129).
Inappropriate and/or irregular use of the system – a social
and behavioural bias – cannot be identified in the data analy-
sis. This can compromise the scientific validity of the entire
results. Furthermore, opportunities to address behavioural or
psychological markers are not seized, even when they are
already identified as possible candidates by practitioners. It is
therefore both mandatory and potentially highly valuable to
properly address usage problems at the patients’ end and to
ensure the usability of a selected mobile application.
The involvement and commitment of the patients and of
the healthcare and social professionals involved from
the start and during all phases of the project is the only
way to address the problem. It is highly recommended to
adopt a co-design/co-evaluation and user-centred design
approach to the project (130). This will be a lever to gain
long-term adherence of both patients and health care provi-
ders. The participation of Living Labs for Health and Auton-
omy will secure the many tasks to be carried out throughout
the project with the users and all participants. It will ensure
a proper usage validity of the collected data right from the
first phases:
• Analysis of the context of use.
• Co-design of the protocol with patients and physicians.
• Evaluation/optimization of device usability, human
machine interface and adoption potential.
• Follow-up of device usage during the collecting phase.
Additional tools
An e-CRF and an e-learning tool will be added to the
MACVIA-ARIA suite of instruments.
MASK: the global and integrated ICT answer for unmet
needs in allergic rhinitis : empowerment of patients
Electronic monitoring of the pollen season
Mobile phone messaging facilitates the management of AR
(131) and chronic diseases (132, 133). Using cell phones with
a touch screen, patients are geolocalized and can evaluate
their symptoms daily by VAS (Figure 2). At the predicted
time of the pollen season, based on local calendars and/or
forecast models where available, patients receive an SMS and
an E-mail indicating that they should monitor VAS daily for
global symptoms on the dedicated mobile device. This infor-
mation is coded and sent to a central database. Daily, 4 VAS
assessments (global evaluation, nasal, ocular and bronchial
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symptoms) are completed by the patient on a cell phone. The
information is sent to a clinical decision support system
(CDSS) for an optimal management of all the patients using
the system. The system is initially being deployed in 13
countries with 14 languages (translation and back-translation,
cultural adaptation and legal issues).
MASK-aerobiology is monitored daily and will be com-
pleted with CARAT at the onset of the pollen season and
thereafter every 2 weeks (Figure 3).
Applications include information to patients and to the
media with regard to the pollen season, optimal management
of the patients with allergic symptoms, clinical trials, research
and climate evaluation (Figure 4).
CDSS based on ARIA 2015 to optimize control during
allergen exposure and stratification of patients
The chronic respiratory diseases CDSS (AIRWAYS-CDSS)
is based on the ARIA 2015 revision (in preparation) and will
enable the standardization of patient management. Patients
with uncontrolled disease based on VAS e-health despite opti-
mal treatment according to guidelines will be considered as
SCUAD (severe chronic upper airway diseases) (15) (Fig-
ures 4–6). However, the physicians will determine the strat-
egy to be used for their individual patients. All medications
available in the given country are listed in the App according
to the IMS list of drugs. The CDSS will be available at the
end of 2015.
These two innovative tools (allergy sentinel network and
AIRWAYS-CDSS) will be combined in MASK-rhinitis and
will make it possible to assess some of the unmet needs of
clinical trials in allergic diseases. They will allow optimal
management of the patients, assessment of control, compli-
ance to treatment as well as patient stratification.
Validation of ARIA guidelines
There is a need to validate guidelines using cluster-random-
ized trials to define whether the new strategy is more effective
than a free treatment choice. The International Consensus of
Rhinitis (102) and ARIA 2001 (103) were both validated.
MASK will also be validated using the same methodology
(Figure 7).
MASK-rhinitis, a single tool for the ICP
An ICP has a focus on an interactive and multidisciplinary
pathway (Figure 8). MASK can be used by:
• Patients, to screen for allergic diseases (in a later stage,
biomarkers will help to confirm the allergic origin of the
symptoms).
• Pharmacists, to guide them in the prescription of OTC
medications and direct the uncontrolled patients to physi-
cians.
Daily VAS monitoring
Pollen season
CARAT + + +
2 weeks 2 weeks
CDSS to op!mize treatment
Informa!on of the begining
of the pollen season
Days
Figure 3 Combination of MASK-aerobiology, CARAT and CDSS.
Pollen counts
in previous years
SMS to inform pa!ent to start VAS daily monitoring 
Increased VAS level
SMS to inform all pa!ents of 
onset of pollen season Informa!on to media
Modelling of future
pollen seasons
Daily VAS level monitoring 
Clinical trialsResearch Policies andpreven!ve strategies
Analysis of clinical and climatologic
data and pollen counts
2 weeks before expected season
best worst
Daily VAS level
b
e
st
w
o
rs
t
Pa!ents selected by MACVIA centers
- History of allergic symptoms
- Posi!ve skin tests (GA2 LEN ba#ery)
- Component resolved IgE
Figure 4 The MASK ICT strategy and usage.
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• The primary care physician, to prescribe appropriate
treatment and to follow up with the patient according to
the physician’s instructions (CDSS) and assessment of
control.
• The specialist, if there is failure to gain control by the
primary physician.
These tools should be customized to be applicable
globally.
Clinical trials
These three innovative tools (CARAT, allergy sentinel net-
work and AIRWAYS-CDSS) are combined in MASK-rhini-
tis and will make it possible to perform innovative clinical
trials in AR (Figure 9) including trials of allergen-specific
immunotherapy (64, 134).
• Phenotypic characterization of allergic patients with strat-
ification of patient severity, characterization of patients
with SCUAD and characterization of patients to be trea-
ted.
• Randomized controlled trials (placebo-controlled or real-
life cluster-randomized trials).
• Follow-up of patients in clinical settings during treat-
ment.
• Follow-up of patients in clinical settings after treatment
has been stopped (persistent effects).
• Assessment of side-effects due to treatment.
Implementation and application of MASK-rhinitis
Promotion of active and healthy ageing
The developmental origin of ageing is on the EU political
agenda. The Polish Priority of the EU Council (2011) pro-
moted the recognition, prevention and management of CRDs
in children to ultimately impact AHA (1095). The develop-
mental determinants of chronic diseases in ageing were rein-
forced during the Cyprus Presidency of the EU Council
(2012), which proposed to fight against NCDs across the life
cycle (135). A meeting at the European Parliament organized
by the Region Languedoc Roussillon under the auspices of
the Cyprus EU Priority (November 2012) was focused on
CRDs (136). MASK-rhinitis will help to detect symptomatic
patients early, to improve management, to increase school
and work productivity and, ultimately, to promote AHA.
Early detection of symptomatic patients
One of the major problems of patients suffering from pollen
allergy is the identification of the onset of the pollen season
at home as well as alertness when pollen peaks are to be
expected. Another problem is when travelling to regions
where the seasons of pollens eliciting symptoms may differ
compared to home (Table 1). As patients will be geolocal-
ized, they will be informed about the level of the pollen sea-
son and will also be able to determine the season when
travelling using MASK-rhinitis.
Stratification of patients with severe allergic diseases
Patient stratification is needed to identify patients with
SCUAD, those for whom specific immunotherapy or other
interventions are appropriate. This is critical for the delivery of
a cost-effective health system. Although all studies are not con-
sistent, in many diseases, ICT tools, ICPs, e-health and CDSS
are likely to define the phenotypes of allergic patients. The
main challenge for allergic diseases in the 21st century is to
understand their complexity. The vast majority of AR patients
can be treated using a simple algorithm. However, a substan-
tial number of these patients are uncontrolled despite treat-
ment (16) and require a personalized (tailored) approach.
Clinical trials
In specific immunotherapy RCTs, it is recommended to
monitor pollen counts in order to determine the onset of the
season and to correlate counts with symptoms. As discussed
earlier, pollen counts alone may misrepresent exposure, espe-
cially if performed at a locality that is remote to that of a
particular patient. As a result of such potential confounders,
unconvincing data have been produced and a placebo-based
Figure 5 Screen of the App.
Increased VAS level
best worst Daily VAS level
Clinical decision
support system
Integrated care pathways
AIRWAYS-ICP
Precise paƟent phenotype
CaracterizaƟon of
SCUAD paƟents
ARIA 2015
Figure 6 MASK CDSS.
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method was found to be more effective (137). Moreover,
there is a need to define the peak pollen season. MASK-
rhinitis is suitable for this approach (64).
Scientific studies
Not all patients respond to pharmacologic treatment and/or
immunotherapy. Research is needed in well-phenotyped
patients to find novel therapeutic approaches. MASK-rhinitis
can help characterize patients so that they can be stratified in
further analyses. Global partnerships and platforms should
ensure the application of standard methodology and proto-
cols in the collection and sharing of samples and data (138).
Assessment of the effects of climate change and land use
Climate change impacts aeroallergens, particularly pollen
(139) and moulds (140). The potential effect of land-use
changes on pollen release may interact with climate change
(141). Allergenic pollens are well known in Europe (66), but
climate change can exert a range of effects on pollen
(142–146). Pollination may start earlier in the future due to
climate change (147, 148). The duration of the pollen season
is extended in some species. Some plants produce a greater
quantity of pollen (149–151) or pollen with stronger aller-
genicity (152–155) under modified climatic conditions. New
allergenic pollen types can appear and result in patients
developing new allergies (e.g. ragweed pollen). The pattern of
change will vary regionally depending on latitude, altitude,
rainfall and storms, land-use patterns, urbanization, trans-
portation and energy production (156).
An integrated approach is needed to anticipate a higher
allergic disease burden that will affect clinical practice and
public health planning. A number of practical prevention
strategies need to be proposed to meet this unprecedented
public health challenge and to combat inequities. Both adap-
tion and mitigation will be needed to counteract the effects
of climate change in allergy (Table 2).
Implementation of the European Environment and
Health
Continued support will be provided to research addressing
the aims of the major policy initiatives such as the European
StraƟfy paƟents
Increased VAS level
best worst Daily VAS level
Clinical decision
support system
Randomized control trials
Assessment of SCUAD
asthma-conjuncƟviƟs
Integrated care pathways
ARIA-ICP
Applicable
to all age groups
and the elderly
Symptoms
MedicaƟons
QOL
ARIA 2015
Figure 9 Clinical trials using MASK-rhinitis.
Table 1 Implications of MASK-rhinitis in early detection of pollen
allergy
Early premedical diagnosis
Optimal treatment proposed to control symptoms and prevent
severe disease (e.g. asthma exacerbations)
Optimal duration of the treatment
Reduction in costs incurred by pollen allergy
best worst
Treat paƟent up to control or
maximum therapy
Integrated care pathways
ARIA-ICP
Clinical decision
Support system
Characterize respondersOpƟmize treatment
PaƟents 
treated by
physicians
« free choice »
Compare the 2 strategies
Daily VAS level
Figure 7 Validation of MASK in a cluster-randomized trial to evalu-
ate guidelines.
Pharmacist
Specialist
Emergency care (asthma)
Self-management
Improvement
Failure
Improvement
Failure
Treatment
Incorrect
diagnosis
severity
Incorrect
diagnosis
severity
Primary care
Patient with allergic rhinitis symptoms
OTC
medicaƟon
Check for
asthma
YES
Figure 8 ICP for MASK-rhinitis.
Table 2 Implications of MASK-rhinitis in climate change and land
use
To detect new sensitizations using pollen counts or derived
methods
To detect changes in pollen seasons
To develop policies for prevention
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Environment and Health Action Plan (2004–2010), the Fifth
Ministerial Conference on Environment and Health and the
EU Sustainable Development Strategy with its environment
and public health components. MASK-rhinitis also includes
strong socio-economic perspectives. In the medium term, it
will ensure the engagement of relevant stakeholders (e.g., user
groups, civil society organizations, policymakers) and it will
cultivate a multidisciplinary approach (including researchers
from social sciences and humanities).
Policies and public health planning
In clinical epidemiology and public health, a uniform defini-
tion of AR and severity is needed to identify prevalence,
burden and costs, to improve quality of care and to optimize
healthcare planning and policies.
MASK: from the ARIA 2015 guideline to an integrated
health system for allergic rhinitis and its asthma
comorbidity
There is an urgent need to propose an innovative health sys-
tem for one of the most common global diseases. Around
20% of the EU population suffers from AR and the costs
are very high, particularly the indirect costs. Although most
patients can self-manage their symptoms, many need OTC
drugs from the pharmacists and a few (but still in millions of
subjects) need medical advice. Fewer, but still in millions, will
need specialist advice. It is very important that a common
language is used between patients and pharmacists, primary
care and specialists. MASK is able to provide this common
language using e-health and a very simple tool (VAS). More-
over, the CDSS will help patients to self-manage under the
control of their physicians. Adding CARAT or other tools,
an economic evaluation can be provided to assess the benefits
and cost savings (indirect and direct costs) of interventions
(5). A warning on asthma is in place in MASK allowing the
assessment of this important comorbidity in AR patients.
Reimbursement patterns can also be monitored and health
system stratification made possible (157). MASK based on
ARIA 2015 appears to be in a unique position to make the
links between all stakeholders.
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